Although Bayer’s top-selling drug Xarelto lost market exclusivity in most geographies in 2024, the company still predicts it will see strong growth from the pharma business unit beginning in 2027.

Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Using a run-of-the-mill, portable and non-invasive electrical muscle stimulator while doing resistance training can yield greater gains in muscle strength and muscle mass than doing resistance ...

Bayer was founded in the year 1863 in Barmen in North Rhine Westphalia in the west of what was then the Kingdom of Prussia, today modern Germany. "What started as a small but innovative dyestuffs ...

Bayer's venerable testosterone replacement product ... Grünenthal is paying up to €500 million ($501 million) for rights to Nebido (testosterone undecanoate), which is sold in around 80 ...

Public Storage Dep. Pfd. (Rep. 1/1000th Share 3.875% Cum. Pfd. Series N) 3.32% Public Storage Dep. Pfd. (Rep. 1/1000th 4.7% Cum. Pfd. SBI Series J) 2.27% Public Storage Dep. Pfd. (Rep. 1/1000 ...

2-Year U.S. Treasury Note Continuous Contract $102.797-0.008-0.01% 5-Year U.S. Treasury Note Continuous Contract $106.227-0.039-0.04% 10-Year U.S. Treasury Note Continuous Contract $108.547-0.063 ...